Lex­eo Ther­a­peu­tics joins small class of 2023 biotech IPOs in $100M Nas­daq list­ing

Lex­eo Ther­a­peu­tics will be­gin trad­ing on the Nas­daq on Fri­day morn­ing via a $100 mil­lion ini­tial pub­lic of­fer­ing.

The car­diac and Alzheimer’s gene ther­a­py biotech priced at $11 per share $LX­EO. In a sign of the drea­ry year for biotech list­ings, Lex­eo priced $2 per share be­low the low end of the range it pro­posed on Mon­day. The Wall Street de­but en­tails sell­ing 9.09 mil­lion shares, which is slight­ly above the 9 mil­lion it had pen­ciled in ear­li­er this week. Lex­eo said Thurs­day night it would al­so give un­der­writ­ers an op­tion to buy an­oth­er 1.36 mil­lion shares with­in 30 days.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER